Factor Model (net -0.3)
Factor Model
net -0.3 1.4 / 10Biotech R&D pullback pressures CRO growth engine
Watch: Watch for stabilization in biotech R&D spending trends in CRL's next earnings call. A rebound in client budgets or guidance that suggests pricing power in contract renewals would signal the bottom is in.
Charles River Laboratories faces near-term headwinds from slowing biotech and pharma R&D spending — a direct hit to its core business as a contract research organization (CRO). The stock is down 2% over the past month and trades at $179.58, though institutional confidence remains steady: hedge fund ownership grew to 53 portfolios in Q4 2025 from 50 in the prior quarter. The pullback appears tactical rather than structural, with Invesco identifying a valuation discount relative to intrinsic value.
CRL's exposure to cyclical biotech spending means near-term growth will soften if the sector's R&D budget climate doesn't recover soon. However, the uptick in hedge fund holding suggests informed capital sees the dip as temporary and the stock as undervalued — a potential sign that the spending headwind is priced in and reversible.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when CRL changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.